Core--ES Cell and Microinjection Facility

核心--ES细胞及显微注射设备

• 批准号: 7071812
• 负责人: MICHAEL J SCHNEIDER
• 金额: $ 16.81万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7071812
• 关键词: biomedical facility; cardiogenesis; developmental genetics; embryonic stem cell; genetically modified animals; laboratory mouse; mammalian embryology; microinjections; tissue mosaicism

The component studies in this Program Project on the genetics of early cardiac development share a technical and biological focus on the mouse as the organism studied. Among vertebrates, only the mouse permits so robust a range of genetic manipulations. The projects involve creating mutations in the germ line and somatic tissues of mice by performing homologous recombination in ES cells, or Cre/IoxP recombination in vivo. Other needs include the creation of mice harboring a bacterial artificial chromosome (BAC), conventional transgene, inducible transgene, or engineered cells that are introduced into blastocysts. These procedures for manipulation of ES cells and the construction of mice are technically demanding and most efficiently performed in a dedicated core laboratory. All of these alleles and technologies have been successfully implemented by the Core Directors, and many of the specific innovations were developed through prior support of this Project.

该计划项目中关于早期心脏发展遗传学的组件研究在研究时对小鼠具有技术和生物学的关注。在脊椎动物中，只有小鼠才允许强大的一系列遗传操作。这些项目涉及通过在ES细胞中进行同源重组或体内CRE/IOXP重组来在细菌线和小鼠的体细胞组织中产生突变。其他需求包括创建具有细菌人造染色体（BAC），常规转基因，诱导转基因或引入胚泡的工程细胞的小鼠。这些操纵ES细胞和小鼠的结构的方法在技术上是苛刻的，并且在专用的核心实验室中最有效地执行。所有这些等位基因和技术都是由核心主管成功实施的，许多特定的创新都是通过此项目的事先支持而开发的。